Shandong Historical Income Statement

600529 Stock

24.60 0.41 1.64%

Historical analysis of Shandong Pharmaceutical income statement accounts such as Selling General Administrative of 177.4 M, Total Revenue of 6 B or Operating Income of 1.1 B can show how well Shandong Pharmaceutical Glass performed in making a profits. Evaluating Shandong Pharmaceutical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Shandong Pharmaceutical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Shandong Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Shandong Pharmaceutical is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shandong Pharmaceutical Glass. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Shandong Income Statement Analysis

Shandong Pharmaceutical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Shandong Pharmaceutical shareholders. The income statement also shows Shandong investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Shandong Pharmaceutical Income Statement Chart

At present, Shandong Pharmaceutical's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 6 B, whereas Selling General Administrative is forecasted to decline to about 177.4 M.

Selling General Administrative Total Revenue Operating Income Cost Of Revenue

Total Revenue

Total revenue comprises all receipts Shandong Pharmaceutical generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Operating Income

Operating Income is the amount of profit realized from Shandong Pharmaceutical operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Shandong Pharmaceutical Glass is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Cost Of Revenue

Cost of Revenue is found on Shandong Pharmaceutical income statement and represents the costs associated with goods and services Shandong Pharmaceutical provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Shandong Pharmaceutical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Shandong Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shandong Pharmaceutical Glass. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2022	2023	2024	2025 (projected)
Operating Income	707.2M	898.9M	1.0B	1.1B
Total Revenue	4.2B	5.0B	5.7B	6.0B

Operating Income Total Revenue

Shandong Pharmaceutical income statement Correlations

	Selling General Administrative	Total Revenue	Operating Income	Cost Of Revenue	Income Before Tax	Net Income	Income Tax Expense	Minority Interest	Research Development	Gross Profit	Other Operating Expenses	Net Income From Continuing Ops	Ebit	Total Operating Expenses	Total Other Income Expense Net	Tax Provision	Net Interest Income	Interest Income	Ebitda	Reconciled Depreciation
Selling General Administrative		-0.08	-0.18	-0.1	-0.16	-0.18	-0.05	0.61	-0.17	-0.19	0.07	-0.25	-0.3	-0.22	-0.22	-0.17	-0.18	-0.15	-0.33	-0.27
Total Revenue	-0.08		0.99	1.0	0.99	0.99	0.76	0.57	0.83	0.9	-0.39	0.89	0.87	0.89	0.81	0.87	0.96	0.94	0.89	0.87
Operating Income	-0.18	0.99		0.98	1.0	1.0	0.79	0.49	0.87	0.93	-0.32	0.92	0.91	0.9	0.85	0.89	0.97	0.95	0.92	0.86
Cost Of Revenue	-0.1	1.0	0.98		0.99	0.99	0.73	0.54	0.81	0.88	-0.43	0.89	0.87	0.9	0.79	0.87	0.96	0.94	0.89	0.88
Income Before Tax	-0.16	0.99	1.0	0.99		1.0	0.77	0.48	0.85	0.92	-0.37	0.92	0.9	0.91	0.85	0.89	0.98	0.96	0.92	0.88
Net Income	-0.18	0.99	1.0	0.99	1.0		0.77	0.47	0.86	0.93	-0.36	0.92	0.91	0.91	0.86	0.89	0.98	0.96	0.92	0.88
Income Tax Expense	-0.05	0.76	0.79	0.73	0.77	0.77		0.5	0.92	0.9	-0.08	0.89	0.92	0.84	0.79	0.83	0.68	0.62	0.87	0.76
Minority Interest	0.61	0.57	0.49	0.54	0.48	0.47	0.5		0.38	0.37	-0.06	0.34	0.35	0.34	0.33	0.32	0.39	0.38	0.33	0.3
Research Development	-0.17	0.83	0.87	0.81	0.85	0.86	0.92	0.38		0.92	-0.12	0.91	0.92	0.86	0.9	0.83	0.79	0.74	0.89	0.77
Gross Profit	-0.19	0.9	0.93	0.88	0.92	0.93	0.9	0.37	0.92		-0.25	0.99	0.97	0.96	0.87	0.96	0.89	0.86	0.95	0.89
Other Operating Expenses	0.07	-0.39	-0.32	-0.43	-0.37	-0.36	-0.08	-0.06	-0.12	-0.25		-0.34	-0.24	-0.44	-0.08	-0.45	-0.46	-0.49	-0.41	-0.6
Net Income From Continuing Ops	-0.25	0.89	0.92	0.89	0.92	0.92	0.89	0.34	0.91	0.99	-0.34		0.97	0.99	0.85	0.97	0.89	0.86	0.98	0.94
Ebit	-0.3	0.87	0.91	0.87	0.9	0.91	0.92	0.35	0.92	0.97	-0.24	0.97		0.95	0.83	0.91	0.84	0.8	0.97	0.89
Total Operating Expenses	-0.22	0.89	0.9	0.9	0.91	0.91	0.84	0.34	0.86	0.96	-0.44	0.99	0.95		0.79	0.97	0.88	0.86	0.97	0.98
Total Other Income Expense Net	-0.22	0.81	0.85	0.79	0.85	0.86	0.79	0.33	0.9	0.87	-0.08	0.85	0.83	0.79		0.78	0.81	0.77	0.83	0.7
Tax Provision	-0.17	0.87	0.89	0.87	0.89	0.89	0.83	0.32	0.83	0.96	-0.45	0.97	0.91	0.97	0.78		0.9	0.89	0.94	0.95
Net Interest Income	-0.18	0.96	0.97	0.96	0.98	0.98	0.68	0.39	0.79	0.89	-0.46	0.89	0.84	0.88	0.81	0.9		1.0	0.89	0.87
Interest Income	-0.15	0.94	0.95	0.94	0.96	0.96	0.62	0.38	0.74	0.86	-0.49	0.86	0.8	0.86	0.77	0.89	1.0		0.85	0.86
Ebitda	-0.33	0.89	0.92	0.89	0.92	0.92	0.87	0.33	0.89	0.95	-0.41	0.98	0.97	0.97	0.83	0.94	0.89	0.85		0.95
Reconciled Depreciation	-0.27	0.87	0.86	0.88	0.88	0.88	0.76	0.3	0.77	0.89	-0.6	0.94	0.89	0.98	0.7	0.95	0.87	0.86	0.95

Click cells to compare fundamentals

Shandong Pharmaceutical Account Relationship Matchups

Shandong Pharmaceutical income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	2.3M	2.8M	2.6M	226.8K	260.8K	512.3K
Selling General Administrative	115.5M	112.3M	135.9M	182.9M	210.3M	177.4M
Total Revenue	3.4B	3.9B	4.2B	5.0B	5.7B	6.0B
Operating Income	718.5M	732.2M	707.2M	898.9M	1.0B	1.1B
Cost Of Revenue	2.3B	2.7B	3.1B	3.6B	4.1B	4.3B
Income Before Tax	653.5M	688.7M	708.1M	910.8M	1.0B	1.1B
Net Income Applicable To Common Shares	458.7M	564.4M	591.1M	618.3M	711.0M	746.6M
Net Income	564.4M	591.1M	618.3M	775.8M	892.2M	936.8M
Income Tax Expense	87.4M	89.0M	97.6M	89.8M	103.2M	52.4M
Research Development	141.3M	136.8M	138.9M	137.9M	158.6M	103.4M
Gross Profit	1.1B	1.1B	1.1B	1.4B	1.6B	1.1B
Other Operating Expenses	29.3M	32.1M	31.2M	23.0M	20.7M	24.2M
Net Income From Continuing Ops	564.4M	591.1M	618.3M	775.8M	892.2M	484.4M
Ebit	526.8M	661.4M	678.8M	707.2M	813.3M	532.3M
Total Operating Expenses	2.7B	3.1B	3.5B	4.1B	4.7B	2.8B
Tax Provision	89.0M	97.6M	89.8M	135.0M	155.3M	91.6M
Net Interest Income	13.5M	10.8M	12.5M	22.7M	26.1M	27.4M
Interest Income	14.7M	10.9M	12.2M	25.7M	29.6M	31.0M
Ebitda	713.4M	869.1M	926.6M	1.0B	1.2B	831.8M
Reconciled Depreciation	217.9M	240.6M	295.2M	325.1M	373.9M	242.1M

Currently Active Assets on Macroaxis

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin
ADA	Cardano
XRP	XRP

Other Information on Investing in Shandong Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Shandong Historical Income Statement

About Shandong Income Statement Analysis

Shandong Pharmaceutical Income Statement Chart

Total Revenue

Operating Income

Cost Of Revenue

Shandong Pharmaceutical income statement Correlations

Shandong Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Shandong Pharmaceutical income statement Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in Shandong Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 1.0	Total Revenue
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Net Income	+ 1.0	Income Before Tax
Interest Income	+ 1.0	Net Interest Income
Operating Income	+ 0.99	Total Revenue

Reconciled Depreciation	- 0.6	Other Operating Expenses
Interest Income	- 0.49	Other Operating Expenses
Net Interest Income	- 0.46	Other Operating Expenses
Tax Provision	- 0.45	Other Operating Expenses
Total Operating Expenses	- 0.44	Other Operating Expenses
Other Operating Expenses	- 0.43	Cost Of Revenue